Literature DB >> 24549591

Morphology predicts BRAF (V⁶⁰⁰E) mutation in papillary thyroid carcinoma: an interobserver reproducibility study.

Renu K Virk1, Constantine G A Theoharis, Avinash Prasad, David Chhieng, Manju L Prasad.   

Abstract

Papillary thyroid carcinomas (PTC) with BRAF (V600E) mutation are morphologically distinctive. They are typically classic or tall cell variants, show infiltrative borders, and are associated with desmoplasia/fibrosis, psammoma bodies, and well-developed nuclear features of papillary carcinoma. We hypothesize that morphologic features of PTC can help in the prediction of BRAF (V600E) mutation, and we evaluate the accuracy and the interobserver reproducibility of such prediction. Hematoxylin and eosin-stained sections from 50 PTCs comprising of 26 mutation-positive and 24 mutation-negative tumors were examined. BRAF (V600E) mutation was predicted correctly in 42/50 tumors (accuracy, 84 %) with 96 % sensitivity, 71 % specificity, and 78 % positive and 94 % negative predictive values (NPV). Subtle nuclear features of PTC (n = 10) had the highest (100 %) negative predictive value followed by well-circumscribed non-infiltrative tumor borders (17/22 mutation-negative tumors, 95 % NPV). The positive predictive value of infiltrative tumor borders (21/28 [75 %] mutation-positive), desmoplasia/fibrosis (23/31 [74 %] mutation-positive), and psammoma bodies (13/20 [65 %] mutation-positive) increased to 100 % when all three features were present (n = 8/8 mutation-positive). To assess interobserver reproducibility, two pathologists blinded to the mutational status evaluated 30 PTCs (15 mutation-positive and 15 mutation-negative) after self-training on 10 PTCs with known BRAF (V600E) mutational status (five mutation-positive and five mutation-negative). The prediction of the mutation was achieved with substantial agreement (κ value, 0.79) and accuracy (25/30, 83 %). This study demonstrates that BRAF (V600E) mutation in papillary thyroid carcinoma can be predicted on morphology with accuracy and with substantial interobserver agreement.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24549591     DOI: 10.1007/s00428-014-1552-3

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  23 in total

1.  Kappa statistic.

Authors:  Christopher R Carpenter
Journal:  CMAJ       Date:  2005-07-05       Impact factor: 8.262

2.  BRAF is a therapeutic target in aggressive thyroid carcinoma.

Authors:  Giuliana Salvatore; Valentina De Falco; Paolo Salerno; Tito Claudio Nappi; Stefano Pepe; Giancarlo Troncone; Francesca Carlomagno; Rosa Marina Melillo; Scott M Wilhelm; Massimo Santoro
Journal:  Clin Cancer Res       Date:  2006-03-01       Impact factor: 12.531

3.  Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation.

Authors:  Linwah Yip; Marina N Nikiforova; Sally E Carty; John H Yim; Michael T Stang; Mitchell J Tublin; Shane O Lebeau; Steven P Hodak; Jennifer B Ogilvie; Yuri E Nikiforov
Journal:  Surgery       Date:  2009-12       Impact factor: 3.982

4.  The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.

Authors:  Tae Hyuk Kim; Young Joo Park; Jung Ah Lim; Hwa Young Ahn; Eun Kyung Lee; You Jin Lee; Kyung Won Kim; Seo Kyung Hahn; Yeo Kyu Youn; Kwang Hyun Kim; Bo Youn Cho; Do Joon Park
Journal:  Cancer       Date:  2011-08-31       Impact factor: 6.860

5.  Papillary thyroid carcinomas with and without BRAF V600E mutations are morphologically distinct.

Authors:  Alexander Finkelstein; Gillian H Levy; Pei Hui; Avinash Prasad; Renu Virk; David C Chhieng; Tobias Carling; Sanziana A Roman; Julie A Sosa; Robert Udelsman; Constantine G Theoharis; Manju L Prasad
Journal:  Histopathology       Date:  2012-02-15       Impact factor: 5.087

6.  Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases.

Authors:  Fulvio Basolo; Liborio Torregrossa; Riccardo Giannini; Mario Miccoli; Cristiana Lupi; Elisa Sensi; Piero Berti; Rossella Elisei; Paolo Vitti; Angelo Baggiani; Paolo Miccoli
Journal:  J Clin Endocrinol Metab       Date:  2010-07-14       Impact factor: 5.958

7.  BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC.

Authors:  Paula Soares; Vítor Trovisco; Ana Sofia Rocha; Jorge Lima; Patrícia Castro; Ana Preto; Valdemar Máximo; Tiago Botelho; Raquel Seruca; Manuel Sobrinho-Simões
Journal:  Oncogene       Date:  2003-07-17       Impact factor: 9.867

8.  BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer.

Authors:  Mingzhao Xing; Douglas Clark; Haixia Guan; Meiju Ji; Alan Dackiw; Kathryn A Carson; Matthew Kim; Anthony Tufaro; Paul Ladenson; Martha Zeiger; Ralph Tufano
Journal:  J Clin Oncol       Date:  2009-05-04       Impact factor: 44.544

9.  Phase II trial of sorafenib in metastatic thyroid cancer.

Authors:  Richard T Kloos; Matthew D Ringel; Michael V Knopp; Nathan C Hall; Mark King; Robert Stevens; Jiachao Liang; Paul E Wakely; Vasyl V Vasko; Motoyasu Saji; Jennifer Rittenberry; Lai Wei; Daria Arbogast; Minden Collamore; John J Wright; Michael Grever; Manisha H Shah
Journal:  J Clin Oncol       Date:  2009-03-02       Impact factor: 44.544

10.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

View more
  6 in total

1.  Is morphology alone able to predict BRAF-mutated malignancies on thyroid FNAC?

Authors:  Esther Diana Rossi; Tommaso Bizzarro; Guido Fadda; Luigi Maria Larocca; Fernando Schmitt
Journal:  Virchows Arch       Date:  2014-06-14       Impact factor: 4.064

2.  The expression of monocarboxylate transporters in thyroid carcinoma can be associated with the morphological features of BRAF V600E mutation.

Authors:  Esther Diana Rossi; Tommaso Bizzarro; Sara Granja; Maurizio Martini; Sara Capodimonti; Emilia Luca; Guido Fadda; Celestino Pio Lombardi; Alfredo Pontecorvi; Luigi Maria Larocca; Fatima Baltazar; Fernando Schmitt
Journal:  Endocrine       Date:  2016-08-02       Impact factor: 3.633

3.  Frequent BRAF V600E and Absence of TERT Promoter Mutations Characterize Sporadic Pediatric Papillary Thyroid Carcinomas in Japan.

Authors:  Naoki Oishi; Tetsuo Kondo; Tadao Nakazawa; Kunio Mochizuki; Tomohiro Inoue; Kazunari Kasai; Ippei Tahara; Tomonori Yabuta; Mitsuyoshi Hirokawa; Akira Miyauchi; Ryohei Katoh
Journal:  Endocr Pathol       Date:  2017-06       Impact factor: 3.943

Review 4.  Immunohistochemical Biomarkers in Thyroid Pathology.

Authors:  Zubair Baloch; Ozgur Mete; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

Review 5.  Somatic mutations in solid tumors: a spectrum at the service of diagnostic armamentarium or an indecipherable puzzle? The morphological eyes looking for BRAF and somatic molecular detections on cyto-histological samples.

Authors:  Esther Diana Rossi; Maurizio Martini; Tommaso Bizzarro; Fernando Schmitt; Adhemar Longatto-Filho; Luigi Maria Larocca
Journal:  Oncotarget       Date:  2017-01-10

6.  New insights into intranuclear inclusions in thyroid carcinoma: Association with autophagy and with BRAFV600E mutation.

Authors:  Suzan Schwertheim; Sarah Theurer; Holger Jastrow; Thomas Herold; Saskia Ting; Daniela Westerwick; Stefanie Bertram; Christoph M Schaefer; Julia Kälsch; Hideo A Baba; Kurt W Schmid
Journal:  PLoS One       Date:  2019-12-16       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.